Patients with burn wounds are susceptible to wound infection and sepsis. This research introduces a novel burn wound dressing that contains silver nanoparticles (SNPs) to treat infection in a 2-acrylamido-2-methylpropane sulfonic acid sodium salt (AMPS-Na(+) ) hydrogel. Silver nitrate was dissolved in AMPS-Na(+) solution and then exposed to gamma irradiation to form SNP-infused hydrogels. The gamma irradiation results in a cross-linked polymeric network of sterile hydrogel dressing and a reduction of silver ions to form SNPs infused in the hydrogel in a one-step process. About 80% of the total silver was released from the hydrogels after 72 h immersion in simulated body fluid solution; therefore, they could be used on wounds for up to 3 days. All the hydrogels were found to be nontoxic to normal human dermal fibroblast cells. The silver-loaded hydrogels had good inhibitory action against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Results from a pilot study on a porcine burn model showed that the 5-mM silver hydrogel was efficient at preventing bacterial colonization of wounds, and the results were comparable to the commercially available silver dressings (Acticoat(TM) , PolyMem Silver(®) ). These results support its use as a potential burn wound dressing.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.24095DOI Listing

Publication Analysis

Top Keywords

gamma irradiation
12
sterile hydrogel
8
hydrogel dressing
8
burn wounds
8
silver nanoparticles
8
burn wound
8
wound dressing
8
silver
7
hydrogel
5
burn
5

Similar Publications

Effects of a supercritical CO process on the mechanical properties and microarchitecture of trabecular bone using compression testing and microcomputed tomography.

J Mech Behav Biomed Mater

January 2025

Aix Marseille Univ, CNRS, ISM, 13009, Marseille, France; Aix Marseille Univ, APHM, CNRS, ISM, Sainte-Marguerite Hospital, Institute for Locomotion, Department of Orthopaedics and Traumatology, 13009, Marseille, France.

Surgeons frequently use allograft bone due to its osteoconductive, osteoinductive, and osteogenic properties. Preservation processes are employed to clean the allograft, improve its conservation, and ensure its sterilization. Many current processes use the properties of supercritical CO to remove bone marrow.

View Article and Find Full Text PDF

A Three-agent Regimen for Triple Negative Breast Cancer Treatment.

Recent Pat Anticancer Drug Discov

January 2025

Department of Medical Oncology, Affiliated Hospital of Inner Mongolia Medical University, NO1 Tongdao Northern Road, Hohhot, 010050, China.

Background: Triple-negative breast cancer (TNBC) has a poor prognosis with current treatment options. Novel therapeutic strategies are urgently needed to enhance treatment outcomes for TNBC.

Objective: This study evaluated the efficacy of a three-agent regimen compared to existing treatment regimens in a TNBC mouse model, and elucidated its potential mechanisms of action.

View Article and Find Full Text PDF

Radiation therapy uses ionizing radiation (IR) to kill cancer cells. However, during radiotherapy normal cells are also damaged and killed by the generation of reactive oxygen species. Polyphenolic compounds are known to mitigate the damaging effects of radiation.

View Article and Find Full Text PDF

Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment.

J Control Release

January 2025

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal; ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.

Interferon-γ (IFN-γ) is a key mediator in antitumor immunity and immunotherapy responses, yet its clinical application remains restricted to chronic granulomatous disease and malignant osteopetrosis. IFN-γ effectiveness as a standalone treatment has shown limited success in clinical trials and its potential for synergistic effects when combined with immunotherapies is under clinical exploration. A particularly compelling combination is that of IFN-γ with Toll-like receptor (TLR) agonists that holds significant promise for cancer treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!